Studies on the efficacy of Merck’s Keytruda medication on bladder, gastric and 10 other types of cancer will be presented at the European Society for Medical Oncology 2017 Congress through Sept. 12 in Madrid.
The presentations will cover nearly three dozen abstracts that detail research on Keytruda when used to treat a variety of cancers, either alone or along with other medications, according to a press release.
The company has tested the drug with 30 different cancers in more than 500 clinical trials, 300 of which combined Keytruda with other therapies.
The research will feature late-breaking abstracts on nonsmall-cell lung cancer, gastric cancer, urothelial carcinoma, breast cancer and others, plus additional research involving renal cell cancer, two types of melanoma, and pancreatic and colorectal cancer.
Other sessions at the conference will discuss Lynparza, an anticancer drug created by Merck and AstraZeneca.